Acadia Pharmaceuticals | ACAD - Operating Profit


Acadia Pharmaceuticals reported $-4.62M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY -10.31B 30.35B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Prothena USD -27.21M 12.55M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026